Excipient firms that skip lot testing or use alternative analysis methods should justify their decisions according to a new COA guide issued by IPEC Americas.

New innovations in single-use bioprocessing systems are being picked up quicker in Europe than in the US, according to ATMI.

The working year is almost done, time to pause from ‘the business’ and embrace the festive season…go on, give it a big hug. Happy holidays!

BASF is moving en masse into omega-3 - especially if its bid for Norwegian player Pronova is approved - but it is technology gained from its May acquisition of a high-dose omega-3 start-up on a remote Scottish island, that is exciting the German giant.

UK CMO Aesica Pharmaceutical says that working with academia to access cutting edge technologies is critical for contractors that want to meet the demands of the modern drug industry.

Risk-based monitoring for clinical trials was a hot topic at this year’s PCT Europe thanks to recent draft guidances from the FDA and the EMA.

The positive impact drug industry demand for quality is having on the fine chemicals sector was evident at industry trade show CPhI last month according to expert Jan Ramakers.

CMO Cobra Biologics says North America is an obvious place to look at for a facility acquisition.

Catalent says making its technology available to industry will not affect its competitive edge.

Bend Research is “actively” hunting new partnerships similar to its recent alliance with Dow.